Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report), Arcturus Therapeutics (ARCT – Research Report) and PDS Biotechnology (PDSB – Research Report).
Accolade (ACCD)
Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on Accolade today and set a price target of $14.00. The company’s shares closed last Tuesday at $10.45.
According to TipRanks.com, Hettenbach is ranked #448 out of 8548 analysts.
Accolade has an analyst consensus of Moderate Buy, with a price target consensus of $16.20.
See today’s best-performing stocks on TipRanks >>
Arcturus Therapeutics (ARCT)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics, with a price target of $51.00. The company’s shares closed last Tuesday at $26.73.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcturus Therapeutics with a $79.00 average price target, implying a 195.5% upside from current levels. In a report issued on September 15, Piper Sandler also assigned a Buy rating to the stock with a $140.00 price target.
PDS Biotechnology (PDSB)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on PDS Biotechnology, with a price target of $21.00. The company’s shares closed last Tuesday at $5.22.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PDS Biotechnology with a $20.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACCD:
